Mallinckrodt — Merger or Acquisition (February 2014)
12 slides from Mallinckrodt's merger presentation, Feb 11, 2014
Slide 1: Acquisition of Cadence Pharmaceuticals
EXHIBIT 99.3 Acquisition February Pharmaceuticals Cadence 11,of2014
Slide 2: Additional Information and Where to Find It
Additional The an Commission Solicitation/Recommendation THE SOLICITATION/RECOMMENDATION THESE INFORMATION 2/10/2014 offer tender TENDER DOCUMENTS to 1purchase Information offer (“SEC”). OFFER for THAT the norAt and outstanding MATERIALS aCAREFULLY HOLDERS the solicitation Where time Statement the T
Slide 3: Additional Information and Where to Find It (cont.)
The Offer Pharmaceuticals Additional (314) Mallinckrodt You 800-SEC-0330 SEC’s 2/10/2014 may 654-6650. website read to 2copies Information Purchase, file and at for In common www.sec.gov. annual, of copy further addition thethe and any tender quarterly stock information related Where to reports the
Slide 4: Forward-Looking Statements
Forward-Looking Statements synergies looking” •suggested 2/10/2014 general Mallinckrodt’s the commercial uncertainty parties’ availability statements economic of or 3inthe ability indicated this transaction, and of success Statements document approval financing, conditions to within Cadence satisfy
Slide 5: Forward-Looking Statements (cont.)
•Forward-Looking 2/10/2014 the ability Cadence customer cost-containment competition; Mallinckrodt’s product liability Pharmaceuticals’ 4concentration; to realize ability losses Statements efforts anticipated toand receive obtain successfully integrate ofperformance other customers, (cont.) and/or g
Slide 6: Forward-Looking Statements and Additional Information (cont.)
•Forward-Looking and Additional the for of future 2/10/2014 the complex changes conducting foreign litigation information the the fiscal restructuring reimbursement date events year exchange year in reporting 5and hereof information ended laws business and technology ended violations; activities. de
Slide 7: Proposed Acquisition Accelerates Mallinckrodt Specialty Pharmaceuticals Growth
Mallinckrodt Growth Definitive, Reinforce Acquisition Add Support Leverage 2/10/2014 branded, with Mallinckrodt’s Mallinckrodt’s Mallinckrodt’s 6$14/share, expected Proposed Accelerates differentiated, to $1.34 Cadence expansion be position Specialty commitment immediately billion high-growth Acquis
Slide 8: Transaction highlights
Transaction $14.00 Timing Financing Structure Impact Financial Consideration $1.34 EPS3 Significantly All Mallinckrodt 321Closing 2/10/2014 Assuming Adjusted Fully cash immediately billion per diluted expected tender 7Cadence diluted highlights net equity accretive intends equity offer cash mid- ear
Slide 9: Cadence: Focused on Hospital Pain Therapeutics
Cadence Focused ~200 USD 02Revenue1 11.5 50.1 110.5 Strong 2013 2012 2011 Intravenous Approved On 1Calendar 2/10/2014 010formulary millions employees growth on – November 8year Exciting developing acetaminophen and driven revenue utilized growth 2010 byand product inopportunity commercializing for ~
Slide 10: OFIRMEV and MNK-155 in pain management
Pain Chronic type Usage Acute Severe Moderate *Mild levelUnder OFIRMEV MNK-155** 2/10/2014 ** Pipeline expands 9is Mallinckrodt’s indicated review opportunity by forthe FDA branded management specialty of mild pharmaceutical to moderate pain, andportfolio moderate to severe pain with adjunctive opio
Slide 11: OFIRMEV offers a compelling value proposition
OFIRMEV • offers Effective a compelling for thevalue management proposition of mild and to potential moderateforpain, growthand moderate to severe pain when used with adjunctive opioid analgesics • Significant possible value yet to be unlocked given its efficacy, safety and potential health economic
Slide 12: Unlocking value of OFIRMEV
Expanding market UNLOCKING position Mallinckrodt’s VALUE in bulk acetaminophen A business Specialtystrategy Pharmaceuticals Expertise to accelerate in manufacturing segment growth Mallinckrodt in specialty and regulatory has pharmaceuticals themanagement scale, scope Expansion CADX and portfolio Bra